Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Analgesic Agent	NCIT_C241	[Compounds that alleviate pain without loss of consciousness. Analgesics act by various mechanisms including binding with opioid receptors and decreasing inflammation. Choice of analgesic may be determined by the type of pain. These compounds include opioid, non-opioid and adjuvant analgesic agents.]
Neoantigen-based Melanoma-Poly-ICLC Vaccine	NCIT_C112003	[A peptide-based melanoma cancer vaccine consisting of neoantigens and peptides derived from patient-specific melanoma immunogenic epitopes, combined with the immunostimulant poly-ICLC with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based melanoma vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. The adjuvant poly-ICLC, composed of double-stranded RNA molecules of polyinosinic-polycytidylic acid stabilized with poly L-lysine in carboxymethylcellulose, is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens.]
Melanoma Vaccine	NCIT_C2517
p70S6K/Akt Inhibitor MSC2363318A	NCIT_C112004	[An orally available inhibitor of the serine/threonine protein kinases ribosomal protein S6 Kinase (p70S6K) and Akt (protein kinase B), with potential antineoplastic activity. Upon administration, p70S6K/Akt inhibitor MSC2363318A binds to and inhibits the activity of p70S6K and Akt. This prevents the activation of the PI3K/Akt/p70S6K signaling pathway and inhibits tumor cell proliferation in cancer cells that have an overactivated PI3K/Akt/p70S6K signaling pathway. Constitutive activation and dysregulated signaling of the PI3K/Akt/p70S6K pathway are frequently associated with tumorigenesis of many tumor types; targeting multiple kinases in this pathway is more efficacious than targeting a single kinase.]
Adenovirus 5-Human Guanylyl Cyclase C-PADRE Vaccine	NCIT_C112005	[A replication-defective, recombinant adenoviral serotype 5 (Ad5) encoding human guanylyl cyclase C (hGCC) and the synthetic Pan DR epitope (PADRE), with potential antineoplastic and immunomodulating activities. Upon intramuscular administration, the Ad5-hGCC-PADRE vaccine expresses hGCC, which may induce both humoral and cellular immune responses against tumor cells expressing the hGCC antigen. This results in the immune-mediated inhibition of tumor cell proliferation, and leads to tumor death. The hGCC protein is normally restricted to intestinal epithelial cells but is overexpressed by metastatic colorectal tumors. PADRE is a helper T-lymphocyte epitope that is able to augment the magnitude and duration of the cytotoxic T-lymphocyte (CTL) response.]
Control Type	NCIT_C49647	[A characteristic of a treatment regimen employed as a comparator against which the study treatment is evaluated.]
Placebo Control	NCIT_C49648	[Use of an inactive compound identical in appearance to drug or treatment being tested in experimental research, which may or may not be known to the physician and/or subject, administered to distinguish between drug action and suggestive effect of the drug or treatment under study. The effects of the active drug or treatment are compared to the effects of the placebo.]
Active Control	NCIT_C49649	[The use of a pharmacologic substance as a control within a treatment regimen where the pharmacologic properties of that substance are relevant to the condition being treated.]
Oraxol	NCIT_C112000	[A combination formulation composed of a capsule containing the taxane compound paclitaxel and a tablet containing the multidrug resistance (MDR) efflux pump P-glycoprotein (P-gp) inhibitor HM30181A, with potential antineoplastic activity. Upon oral administration of oraxol, the HM30181A moiety binds to and inhibits P-gp, which prevents P-gp-mediated efflux of paclitaxel, therefore enhancing its oral bioavailability. In turn, paclitaxel binds to and stabilizes microtubules, preventing their depolymerization, which results in the inhibition of cellular motility, mitosis, and replication. Altogether, this may result in greater intracellular concentration of paclitaxel, and enhanced cytotoxicity against tumor cells, when compared to the administration of paclitaxel alone. P-gp, encoded by the MDR-1 gene, is a member of the ATP-binding cassette (ABC) superfamily of transmembrane transporters; it prevents the intestinal uptake and intracellular accumulation of various cytotoxic agents.]
Anti-LIV-1 Monoclonal Antibody-MMAE Conjugate SGN-LIV1A	NCIT_C112001	[An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the anti-solute carrier family 39 zinc transporter member 6 (SLC39A6; LIV-1; ZIP6) protein that is conjugated, via a protease-cleavable linker, to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration and internalization by LIV-1-positive tumor cells, anti-LIV-1 antibody-drug conjugate SGN-LIV1A undergoes enzymatic cleavage to release MMAE into the cytosol. In turn, MMAE binds to and inhibits tubulin polymerization, which may result in G2/M phase cell cycle arrest and apoptosis in LIV-1-expressing tumor cells. LIV-1, a member of the zinc transporter family, is expressed in several types of solid tumors and plays a key role in tumor cell progression and metastasis. The linkage system in SGN-LIV1A is highly stable in plasma, resulting in cytotoxic specificity against LIV-1-positive cells.]
Cure Study	NCIT_C49654	[A type of study protocol designed to evaluate intervention(s) aimed to cure a disease or condition.]
Clinical Study by Intent	NCIT_C49652	[The name of a code list that contains terms to define the type of trial, e.g. cure or prevention.]
Anti-Carcinoembryonic Antigen Antibody-Carboxypeptidase G2 Fusion Protein MFECP1	NCIT_C74600
Adverse Effect Mitigation Study	NCIT_C49655	[A type of study designed to identify actions necessary to eliminate or reduce the risk to human life or well-being as a result of a particular medication, treatment regimen, procedure, or any other medical intervention.]
Parenchyma	NCIT_C74601	[The tissue that constitutes the essential part of an organ as contrasted with e.g., connective tissue and blood vessels.]
Treatment Study	NCIT_C49656	[A type of study protocol designed to evaluate intervention(s) for disease treatment.]
Mitotic Figure	NCIT_C74602	[The microscopic appearance of a cell undergoing mitosis.]
Prevention Study	NCIT_C49657	[A type of study protocol designed to evaluate intervention(s) for disease prevention.]
Diagnosis Group	NCIT_C49650	[A grouping of individuals on the basis of a shared procedure or disease, or lack thereof (e.g. healthy volunteers, type 2 diabetic subjects, subjects with renal cell cancer). Standardized naming systems are available that define the groups within which a subject should be placed.]
Group	NCIT_C43359	[Any number of entities (members) considered as a unit.]